Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm to Present at the Jefferies 2018 London Healthcare Conference
NEWTON, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14,
View HTML
Toggle Summary Karyopharm Therapeutics to Ring Nasdaq Closing Bell on November 6th
Ceremony to Commemorate Five-Year Listing Anniversary NEWTON, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder Sharon Shacham PhD, MBA, President and Chief
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 127,500 shares of Karyopharm’s
View HTML
Toggle Summary Karyopharm Announces Results of Clinical Studies Investigating Selinexor in Multiple Myeloma and Diffuse Large B-Cell Lymphoma to be Presented at the American Society of Hematology 2018 Annual Meeting
--  Top-line Results from Phase 2b SADAL Study in DLBCL to be Presented --  --  Additional Results from the Pivotal Phase 2b STORM Study in Penta-Refractory Multiple Myeloma and Updated Phase 1b/2 STOMP Data in Relapsed or Refractory Multiple Myeloma to be Highlighted in Oral Presentations -- 
View HTML
Toggle Summary Karyopharm to Report Third Quarter 2018 Financial Results on November 8, 2018
-- Conference Call Scheduled for Thursday, November 8, 2018 at 8:30 a.m. ET --  NEWTON, Mass. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2018 financial results on
View HTML
Toggle Summary Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers’ Option
NEWTON, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has issued an additional $22.5 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “notes”) pursuant to
View HTML
Toggle Summary Karyopharm Therapeutics Announces Management Change
NEWTON, Mass. , Oct. 26, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Mike Falvey , Executive Vice President, Chief Financial Officer and Treasurer, intends  to leave the company to pursue other interests.   Mr.
View HTML
Toggle Summary Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes
NEWTON, Mass. , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of $150 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “Notes”).  The Notes will be sold in a
View HTML
Toggle Summary Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes
NEWTON, Mass. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of convertible senior notes due 2025 (the
View HTML
Toggle Summary U.S. Food and Drug Administration Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review
--  Application Seeks Accelerated Approval for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma  -- --  PDUFA Date Set for April 6, 2019  -- NEWTON, Mass. , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical
View HTML